Anika Therapeutics, Inc. (ANIK)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
ANIK Insider Trading Activity
ANIK Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Insider Activity of Anika Therapeutics, Inc.
Over the last 12 months, insiders at Anika Therapeutics, Inc. have bought $0 and sold $0 worth of Anika Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Anika Therapeutics, Inc. have bought $274,901 and sold $127,818 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,500 shares for transaction amount of $32,055 was made by Colleran David (EVP, General Counsel, Corp Sec) on 2022‑05‑11.
List of Insider Buy and Sell Transactions, Anika Therapeutics, Inc.
| 2022-05-11 | Colleran David | EVP, General Counsel, Corp Sec | 1,500 0.0104% | $21.37 | $32,055 | +22.64% | ||
| 2022-03-14 | Colleran David | EVP, General Counsel, Corp Sec | 1,500 0.0109% | $26.65 | $39,978 | -3.85% | ||
| 2022-03-11 | Blanchard Cheryl R | President, CEO, Director | 3,813 0.0266% | $25.81 | $98,429 | -4.61% | ||
| 2022-03-11 | Thompson Jeffery S | 2,000 0.0133% | $24.66 | $49,318 | -4.61% | |||
| 2022-03-11 | Levitz Michael L | EVP, CFO, Treasurer | 4,000 0.0266% | $24.62 | $98,476 | -4.61% | ||
| 2021-08-12 | Levitz Michael L | EVP, CFO, Treasurer | 777 0.0053% | $40.20 | $31,239 | -23.48% | ||
| 2021-08-11 | Levitz Michael L | EVP, CFO, Treasurer | 2,850 0.0196% | $40.21 | $114,587 | -22.71% | ||
| 2021-05-18 | HENNEMAN JOHN B III | director | 2,000 0.014% | $42.86 | $85,720 | -6.92% | ||
| 2021-05-12 | Sale | LAND RAYMOND J | director | 2,000 0.014% | $42.60 | $85,200 | -5.92% | |
| 2020-11-10 | Sale | LAND RAYMOND J | director | 3,446 0.0232% | $36.77 | $126,709 | +6.14% | |
| 2020-07-09 | Sale | Loerop James | EVP Business Development | 1,244 0.0089% | $35.15 | $43,727 | +8.80% | |
| 2020-02-26 | Sale | LAND RAYMOND J | director | 2,700 0.0192% | $42.68 | $115,236 | -13.87% | |
| 2019-11-08 | Sale | Cheung Sylvia | Chief Financial Officer | 20,000 0.1389% | $59.71 | $1.19M | -39.44% | |
| 2019-08-28 | Sale | Larsen Glenn R. | director | 4,355 0.031% | $57.21 | $249,150 | -27.63% | |
| 2019-08-20 | Sale | Bower Joseph L. | director | 1,994 0.0141% | $55.57 | $110,807 | -24.80% | |
| 2019-08-08 | Sale | Thompson Jeffery S | director | 4,843 0.0345% | $56.66 | $274,404 | -24.77% | |
| 2019-07-29 | Sale | LAND RAYMOND J | director | 3,000 0.0222% | $55.44 | $166,320 | -17.75% | |
| 2019-02-28 | Darling Joseph G | President and CEO; Director | 1,000 0.0072% | $33.20 | $33,200 | +38.89% | ||
| 2019-02-26 | Sale | LAND RAYMOND J | director | 4,000 0.0287% | $33.06 | $132,240 | +39.32% | |
| 2017-11-30 | Sale | Hague Richard | Chief Commercial Officer | 5,250 0.0356% | $54.48 | $286,020 | -23.46% |
Insider Historical Profitability
| Fidia Farmaceutici S.p.A. | 10 percent owner | 711192 4.856% | $11.32M | 0 | 1 | |
| SHERWOOD CHARLES H | CEO and Director | 132791 0.9067% | $2.11M | 0 | 30 | |
| Blanchard Cheryl R | President, CEO, Director | 59992 0.4096% | $954,472.72 | 1 | 0 | <0.0001% |
| WHEELER STEVE E | director | 48219 0.3292% | $767,164.29 | 0 | 9 | |
| Cheung Sylvia | Chief Financial Officer | 47741 0.326% | $759,559.31 | 0 | 2 | |
| Bower Joseph L. | director | 43010 0.2937% | $684,289.10 | 0 | 4 | |
| DAVIDSON EUGENE A | director | 30000 0.2048% | $477,300.00 | 0 | 7 | |
| QUINLAN KEVIN W | Chief Financial Officer | 27112 0.1851% | $431,351.92 | 5 | 2 | +3.86% |
| Hague Richard | Chief Commercial Officer | 23650 0.1615% | $376,271.50 | 0 | 1 | |
| Darling Joseph G | President and CEO; Director | 22436 0.1532% | $356,956.76 | 1 | 0 | +38.89% |
| Thompson Jeffery S | 17121 0.1169% | $272,395.11 | 1 | 4 | <0.0001% | |
| Levitz Michael L | EVP, CFO, Treasurer | 15924 0.1087% | $253,350.84 | 3 | 0 | <0.0001% |
| Moran John C | director | 14803 0.1011% | $235,515.73 | 0 | 5 | |
| HENNEMAN JOHN B III | director | 11310 0.0772% | $179,942.10 | 1 | 0 | <0.0001% |
| SADOW HARVEY S | director | 10000 0.0683% | $159,100.00 | 0 | 9 | |
| Colleran David | EVP, General Counsel, Corp Sec | 9867 0.0674% | $156,983.97 | 2 | 0 | +9.4% |
| LAND RAYMOND J | director | 7953 0.0543% | $126,532.23 | 0 | 13 | |
| Larsen Glenn R. | director | 7590 0.0518% | $120,756.90 | 0 | 1 | |
| Ahn Edward S. | Chief Tech & Strategy Officer | 7260 0.0496% | $115,506.60 | 0 | 1 | |
| Mrachek William | Vice President, Human Resource | 6854 0.0468% | $109,047.14 | 2 | 0 | +13.04% |
| Loerop James | EVP Business Development | 1756 0.012% | $27,937.96 | 0 | 1 | |
| LUPPINO FRANCESCO J | Vice President of Operations | 0 0% | $0 | 0 | 6 | |
| MCKAY SAMUEL F | director | 0 0% | $0 | 0 | 10 |
ANIK Institutional Investors: Active Positions
| Increased Positions | 56 | +37.84% | 1M | +8.09% |
| Decreased Positions | 66 | -44.59% | 2M | -12.23% |
| New Positions | 16 | New | 199,345 | New |
| Sold Out Positions | 28 | Sold Out | 604,862 | Sold Out |
| Total Postitions | 138 | -6.76% | 13M | -4.15% |
ANIK Ownership Change vs Market
Institutional Investor Ownership
| Trigran Investments, Inc. | $35,280.00 | 13.48% | 2.02M | -102,682 | -4.83% | 2024-12-31 |
| Blackrock, Inc. | $27,185.00 | 10.39% | 1.56M | -206,725 | -11.71% | 2024-12-31 |
| Caligan Partners Lp | $25,043.00 | 9.57% | 1.44M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $13,354.00 | 5.1% | 765,270 | -33,373 | -4.18% | 2024-12-31 |
| Alta Fundamental Advisers Llc | $12,223.00 | 4.67% | 700,432 | +404,350 | +136.57% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $11,471.00 | 4.38% | 657,355 | -50,011 | -7.07% | 2024-12-31 |
| Boothbay Fund Management, Llc | $9,240.00 | 3.53% | 529,503 | +25,665 | +5.09% | 2024-12-31 |
| Renaissance Technologies Llc | $9,223.00 | 3.52% | 528,517 | -45,712 | -7.96% | 2024-12-31 |
| Acadian Asset Management Llc | $8,301.00 | 3.17% | 475,713 | +26,929 | +6% | 2024-12-31 |
| Capital Management Corp /Va | $5,681.00 | 2.17% | 325,545 | +35,195 | +12.12% | 2024-12-31 |